KRAS and neoplasm: KRAS allelic variants are found in 20% to 30% of BTCs and have been associated with a more aggressive tumor phenotype and shortened survival.16,17,18 Multiple KRAS inhibitors are currently under investigation for KRAS-mutated tumors.